Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Significant progress in PREVENT-19 study; final data expected in the second quarter of 2021
- Initiated pediatric extension of PREVENT-19 in the U.S.
- Evaluating COVID-19 booster performance in U.S. and Australia Phase 2 and South Africa Phase 2b studies, as well as study with the University of Oxford
- Finalized APA with Gavi to supply 1.1 billion doses for the COVAX Facility
- Company to host conference call today at 4:30 p.m. ET
News provided by
Share this article
Share this article
GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2021.
Vaccine Stocks Checkup: J&J Still to Deliver 100 Million U.S. Doses
See the latest news for the top companies producing COVID-19 vaccines, including Pfizer, Moderna, Sanofi, AstraZeneca and more.
Author:
Original:
Johnson & Johnson (
JNJ) - Get Report posted stronger-than-expected first-quarter earnings and boosted its full-year earnings forecast as sales from medical devices and pharmaceuticals recorded solid post-pandemic gains. Vaccine sales, Johnson & Johnson said, reached $100 million.
The company said adjusted earnings for the three months ending in March came in at $2.59 cents per share, up 12.6% from the same period last year and well ahead of the Street consensus forecast of $2.34 per share. Group revenues, Johnson & Johnson said, rose 7.9% to $22.3 billion, again besting analysts estimates of a $22 billion tally.
Morgan bowls a 300 themountainmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themountainmail.com Daily Mail and Mail on Sunday newspapers.